Clinical Trials
59 trialsNCT00092222 2026-05-22
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT01446133 2026-05-22
Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02427620 2026-05-22
Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02007044 2026-05-20
Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04765111 2026-05-20
Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03710772 2026-05-19
Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05221645 2026-05-15
P+R-ICE
University of Southampton
Phase 2 Active not recruiting
NCT04458610 2026-05-14
Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05453500 2026-05-11
Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia
University of Washington
Phase 2 Active not recruiting
NCT03474744 2026-05-06
Copanlisib and Rituximab in Marginal Zone Lymphoma Patients
University of Ulm
Phase 2 Active not recruiting
NCT04115631 2026-05-05
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT04978584 2026-05-05
Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04546620 2026-04-30
REMoDL-A
University Hospital Southampton NHS Foundation Trust
Phase 2 Active not recruiting
NCT03863184 2026-04-28
Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT02436707 2026-04-20
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT06522386 2026-04-16
GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01424982 2026-04-15
Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01661881 2026-04-08
Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03697512 2026-04-08
MALIBU
International Extranodal Lymphoma Study Group (IELSG)
Phase 2 Active not recruiting
NCT05798156 2026-04-08
R-Pola-Glo
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Active not recruiting
NCT05303792 2026-04-07
Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Active not recruiting
NCT03467867 2026-04-06
A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL
Georgetown University
Phase 2 Active not recruiting
NCT02682641 2026-03-27
Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Active not recruiting
NCT00492050 2026-03-11
Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02446457 2026-03-09
Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02339922 2026-03-05
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
University of Washington
Phase 2 Active not recruiting
NCT03789240 2026-03-03
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT01880567 2026-02-19
Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03147612 2026-02-17
Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04980222 2026-02-17
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT03749018 2026-02-06
Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT04375228 2026-02-06
Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)
Columbia University
Phase 2 Active not recruiting
NCT04624906 2026-02-04
BRAWM
Sunnybrook Health Sciences Centre
Phase 2 Active not recruiting
NCT03943901 2026-01-29
Split-Dose R-CHOP for Older Adults With DLBCL
University of Wisconsin, Madison
Phase 2 Active not recruiting
NCT06425302 2026-01-08
GOLSEEK-2
Celgene
Phase 2 Active not recruiting
NCT04594798 2025-12-17
A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL
University of Rochester
Phase 2 Active not recruiting
NCT03620903 2025-12-05
Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia
University of Ulm
Phase 2 Active not recruiting
NCT05065554 2025-12-05
ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT07247383 2025-11-25
Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Active not recruiting
NCT02251548 2025-10-24
iFCR
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT05951959 2025-10-21
TrAVeRse
AstraZeneca
Phase 2 Active not recruiting
NCT04479267 2025-09-29
Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma
Barbara Ann Karmanos Cancer Institute
Phase 2 Active not recruiting
NCT04665765 2025-09-03
Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
City of Hope Medical Center
Phase 2 Active not recruiting
NCT01810588 2025-09-02
Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT03505762 2025-08-20
Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment
Wake Forest University Health Sciences
Phase 2 Active not recruiting
NCT05788081 2025-08-20
TOP-FLOR
Olivia Newton-John Cancer Research Institute
Phase 2 Active not recruiting
NCT02734771 2025-08-12
BV mini CHP
University of Rochester
Phase 2 Active not recruiting
NCT02790515 2025-08-12
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT00923013 2025-08-08
Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT04416451 2025-07-02
A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting